238 related articles for article (PubMed ID: 34271080)
1. Search for safer and potent natural inhibitors of Parkinson's disease.
Khan ST; Ahmed S; Gul S; Khan A; Al-Harrasi A
Neurochem Int; 2021 Oct; 149():105135. PubMed ID: 34271080
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
[TBL] [Abstract][Full Text] [Related]
3. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
5. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Chen JJ; Fernandez HH
Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in the pharmacological treatment of Parkinson's disease.
Tuite P; Riss J
Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
[TBL] [Abstract][Full Text] [Related]
7. Designing prodrugs for the treatment of Parkinson's disease.
Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
[TBL] [Abstract][Full Text] [Related]
8. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
Maranis S; Tsouli S; Konitsiotis S
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
[TBL] [Abstract][Full Text] [Related]
9. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Pagonabarraga J; Rodríguez-Oroz MC
Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
[TBL] [Abstract][Full Text] [Related]
10. Comparison chart: Drugs for Parkinson's disease.
Med Lett Drugs Ther; 2020 Dec; 62(1613):e1-e9. PubMed ID: 33647002
[No Abstract] [Full Text] [Related]
11. Current pharmacotherapeutic treatment options in Parkinson's disease.
Rezak M
Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
[TBL] [Abstract][Full Text] [Related]
12. [The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].
Szász JA; Constantin V; Fazakas PA; Blényesi E; Grieb LG; Balla A; Sárig M; Szegedi K; Bartha EN; Szatmári S
Orv Hetil; 2017 Dec; 158(51):2023-2028. PubMed ID: 29250969
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
14. Drugs used to treat Parkinson's disease, present status and future directions.
Abdel-Salam OM
CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661
[TBL] [Abstract][Full Text] [Related]
15. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Lees A
Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
Deleu D; Northway MG; Hanssens Y
Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
[TBL] [Abstract][Full Text] [Related]
17. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
Gallagher DA; Schrag A
CNS Drugs; 2008; 22(7):563-86. PubMed ID: 18547126
[TBL] [Abstract][Full Text] [Related]
18. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological treatments of Parkinson's disease].
Nomoto M; Iwata S; Kaseda S
Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):111-22. PubMed ID: 11233302
[TBL] [Abstract][Full Text] [Related]
20. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]